MC1R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
== Pharmacology == The drug is a selective KOR antagonist and shows approximately 10- to 20-fold higher affinity for the KOR (Ki = 1–3 nM) over the μ-opioid receptor (MOR) (Ki = 10–64 nM) and has negligible affinity for the δ-opioid receptor (DOR) (Ki > 4,000 nM). It is a "short-acting" or non-inactivating antagonist of the KOR (as opposed to irreversible antagonists like JDTic). Although originally characterized as a KOR neutral antagonist however, subsequent research revealed in 2020 that PF-04455242 is actually only a moderately efficacious partial antagonist of the KOR (Imax ≈ 50%). In any case, the drug reversed the analgesic and prolactin-elevating effects of the KOR agonist spiradoline in animals, showed efficacy in animal models predictive of antidepressant activity, and reversed stress-induced reinstatement of cocaine-seeking behavior. However, PF-04455242 also showed a variety of other weak off-target activities.
The study was double-blind and placebo-controlled. Patients had HCV GT1, GT4, or GT6 and were on opioid therapy. Upwards of 96% of the patients achieved SVR24. This study contributed to the knowledge of the incidence of HCV reinfection in patients who receive drug injection of opioid treatments. This is a demographic that the medical community is typically reluctant to treat due to concerns of reinfection and compliance.
== Further reading == Serafini M, Cargnin S, Massarotti A, Pirali T, Genazzani AA (September 2020). "Essential Medicinal Chemistry of Essential Medicines". Journal of Medicinal Chemistry. 63 (18): 10170–10187. doi:10.1021/acs.jmedchem.0c00415. PMC 8007110. PMID 32352778. Stuart MC, Kouimtzi M, Hill SR, eds. (2009). WHO Model Formulary 2008. World Health Organization. hdl:10665/44053. ISBN 978-92-4-154765-9. The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015. hdl:10665/189763. ISBN 978-92-4-069494-1. ISSN 0512-3054. WHO technical report series; no. 994. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. 2017. hdl:10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2019. hdl:10665/330668. ISBN 978-92-4-121030-0. ISSN 0512-3054. WHO technical report series;1021. Organization WH (2019).
Sources: en.wikipedia.org
Parmotrema perlatum typically grows in areas with ample light, favouring neutral to slightly acidic-barked broad-leaved trees. It is commonly found on siliceous rocks and walls, as well as mossy coastal rocks, generally growing in places with moderate to strong sunlight. In the Great Smoky Mountains National Park in the United States, Parmotrema perlatum is especially abundant on branches in humid, high-elevation habitats. Similarly, in East Africa, it grows in the misty environments of inselbergs, montane forests, and Erica-dominated habitats, typically found between 1,400 and 3,100 m (4,600 and 10,200 ft) above sea level. The species is globally distributed, found in both temperate and tropical regions. It has been reported across numerous European countries including Austria, Belgium, the Czech Republic, France, Germany, Great Britain, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Scandinavia, Slovakia, Spain, and Ukraine. Although it is rare in Eastern Europe, it is widely distributed in both the Asian and European parts of Russia. Beyond Europe, it is also present in Macaronesia, Africa, Australia, North America, and South America. Its Asian distribution includes India, Japan, Taiwan, and South Korea. Although it has historically been recorded in Nepal and Sri Lanka, these reports are considered tentative due to shifting species concepts and possible confusion with the lookalike Parmotrema pseudonilgherrense.
=== Warehousing and distribution === Warehousing and distribution are major logistics segments, and are among the fastest-growing logistics services in South Africa. Numerous developers have constructed large (30,000 sqm+) warehouse facilities along the N3 and N1 corridors, to facilitate the storage and distribution of consumer goods, including those from e-commerce companies. These warehouses support a retail sector that in 2024 was worth approximately R1.4 trillion. The presence of e-commerce companies such as Takealot, Amazon, AliExpress, Temu, and Shein continues to grow in South Africa, and these companies make extensive use of warehousing. South Africa's food storage capacity as a proportion of production is high, and only slightly behind China's, despite having a population that is 21 times smaller. Warehousing in South Africa is shifting from passive storage to technology-intensive logistics operations. Automation, inventory optimization, and e-commerce fulfilment are driving value-added services beyond traditional storage. Cold chain storage in South Africa is growing, supported by the food and pharmaceutical industries. South Africa's cold chain storage sector is the largest and most mature in Africa. As of 2025, prime rent for warehousing averaged around R100 per sqm, and the average yield (return) was 8.25%. Warehouses tend to be concentrated in and around South Africa's largest cities - most notably Durban, Johannesburg, and Cape Town. The primary use varies between cities.
=== Bacterial nanocellulose === Some cellulose producing bacteria have also been used to produce nanocellulosic materials that are then referred to as bacterial nanocellulose. The most common examples being Medusomyces gisevii (the bacteria involved in the making of Kombucha) and Komagataeibacter xylinus (involve in the fabrication of Nata de coco), see bacterial cellulose for more details. This naming distinction might arise from the very peculiar morphology of these materials compared to the more traditional ones made of wood or cotton cellulose. In practice, bacterial nanocellulosic materials are often larger than their wood or cotton counterparts.
Sources: en.wikipedia.org
On June 22, 2021, the Senate passed the Accelerating Holding Foreign Companies Accountable Act, a bill by Kennedy that moves up the deadline for a bill passed in 2019 that required U.S. markets to delist any foreign company that refused to allow the Public Company Accounting Oversight Board to inspect its audits. Kennedy said, "When foreign companies flout America's security laws, they put Americans' retirement plans and savings at risk. China is bent on exploiting American investors, so we need more accountability for foreign companies using American capital, and we need it now." On July 29, 2021, President Joe Biden signed into law the DUMP Opioids Act, Kennedy's eighth piece of legislation to become law in his first term as a U.S. senator. Kennedy has authored more bills signed into law than any first-term senator from Louisiana except Newton Blanchard. On August 8, 2021, Kennedy voted against the Infrastructure Investment and Jobs Act, saying, "I realized pretty quickly that if you look up 'stupid stuff' in the dictionary, there's a picture of this bill. They told us it was a real infrastructure bill. It's not; only 23% of the bill is real infrastructure. The rest is Green New Deal and welfare. They told us the bill was paid for; it isn't. We're gonna have to borrow maybe up to $400 billion to pay for it. They told us there were no tax increases. There are; my state's gonna have to pay $1.3 billion in new taxes on our petrochemical industry.
== List == The Madras Presidency, based at Fort St. George, was a presidency of India that was established in 1652 by the English East India Company to be the headquarters of the English settlements on the Coromandel Coast. The territory under the presidency consisted of the village of Madrasapattinam and its surrounding regions. After a series of wars including the Anglo-French wars, Anglo-Mysore wars, and Polygar wars, and the consequent alliance with the Nawab of Arcot, it was expanded to cover the region from the Northern Circars to Cape Comorin, and included present-day Tamil Nadu, the Malabar region of North Kerala, the coastal and Rayalaseema regions of Andhra Pradesh, and the Bellary, Dakshina Kannada, and Udupi districts of Karnataka. The Indian Councils Act 1861 set up the Madras Legislative Council as an advisory body, without powers, through which the colonial administration obtained advice and assistance from able and willing Indian leaders. However, the members were appointed and not elected by the public. With the enactment of the Government of India Act 1919, the first elected legislature was formed in 1920 after the general elections. The term of the legislative council was three years. It had 132 members, of whom 34 were nominated by the governor and the rest were elected. As per the Government of India Act 1935, a bicameral legislature was set up with a legislative assembly consisting of 215 members and a legislative council having 56 members. The first legislative assembly under this act was constituted in July 1937.
Selenium at The Periodic Table of Videos (University of Nottingham) National Institutes of Health page on Selenium Assay Archived 2012-02-26 at the Wayback Machine ATSDR – Toxicological Profile: Selenium CDC – NIOSH Pocket Guide to Chemical Hazards Peter van der Krogt elements site
=== Single-layer drug-in-adhesive === The adhesive layer of this system also contains the drug. In this type of patch the adhesive layer not only serves to adhere the various layers together, along with the entire system to the skin, but is also responsible for the releasing of the drug. The adhesive layer is surrounded by a temporary liner and a backing. It is characterized by the inclusion of the drug directly within the skin-contacting adhesive placed onto the epidermis.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.